Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Daily News

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Yael L. Maxwell

March 03, 2021

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Daily News

TCTMD’s Top 10 Most Popular News Stories From 2011

Jason Kahn

March 08, 2012

News Daily News

Statins Reduce Late Restenosis After SES Implantation

Jason Kahn

March 05, 2012

News Daily News

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

L.A. McKeown

August 05, 2011

News Conference News

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Caitlin E. Cox

April 05, 2011

News Daily News

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

L.A. McKeown

January 24, 2011

Advertisement

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

TCTMD’s Top 10 Most Popular News Stories From 2011

Statins Reduce Late Restenosis After SES Implantation

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content